109 growth-stage biotech investors
We list 109 growth-stage biotech investors as of November 2026: 45 have an SEC filing on file and 64 were checked on the firm's own website or an official register, and the list was last checked on 7 Nov 2026. The states with the most are California (11), New York (7) and Massachusetts (5).
Top 5 growth-stage biotech investors, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
Longitude Venture Partners
Type: VC firm · HQ: Menlo Park, CA · Stages: Growth · Focus: Biotech, Healthtech, Medtech · Latest activity: New deal, Jun 2026 · Fund size on file: $600M (SEC Form D, 2022)
Dated new deal in Jun 2026; $600M fund on file (SEC Form D, 2022); 80% of its observed portfolio is biotech and life sciences; backs growth-stage; 8 named decision-makers on file.
Cambridge Innovation Capital
Type: VC firm · HQ: Cambridge, United Kingdom · Stages: Seed, Series A, Growth · Focus: Biotech, Healthtech, AI, Fintech · Latest activity: New fund, Oct 2026 · Fund size or assets: £600M (own site)
Latest fund filing dated Oct 2026; £600M on file (own site); 53% of its observed portfolio is biotech and life sciences; backs seed, Series A, growth-stage; 8 named decision-makers on file.
NewVale Capital
Type: VC firm · HQ: Boulder, CO · Stages: Growth · Focus: Biotech, Healthtech, Medtech · Latest activity: New fund, Oct 2026 · Fund size on file: $250M (SEC Form D, 2026)
Latest fund filing dated Oct 2026; $250M fund on file (SEC Form D, 2026); states biotech and life sciences as a focus; backs growth-stage; 8 named decision-makers on file.
Audere
Type: VC firm · HQ: Austin, TX · Stages: Growth · Focus: Biotech, Cybersecurity, AI, Robotics · Latest activity: New fund, Oct 2026 · Fund size on file: $100M (SEC Form D, 2024)
Latest fund filing dated Oct 2026; $100M fund on file (SEC Form D, 2024); states biotech and life sciences as a focus; backs growth-stage; 8 named decision-makers on file.
JSTAR Capital
Type: VC firm · HQ: Austin, TX · Stages: Growth · Focus: Biotech, Healthtech, AI, Fintech · Latest activity: New fund, Aug 2026 · Fund size on file: $100M (SEC Form D, 2025)
Latest fund filing dated Aug 2026; $100M fund on file (SEC Form D, 2025); 25% of its observed portfolio is biotech and life sciences; backs growth-stage; 8 named decision-makers on file.
First 25 of 109 growth-stage biotech investors
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Biotech, Healthtech, Medtech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 5 Nov 2026 | 8 names · Unlock |
| Cambridge Innovation Capital | VC firm | Cambridge, United Kingdom | Seed, Series A, Growth | Biotech, Healthtech, AI, Fintech | New fund, Oct 2026 | £600M (own site) | 4 Nov 2026 | 8 names, firm email · Unlock |
| NewVale Capital | VC firm | Boulder, CO | Growth | Biotech, Healthtech, Medtech | New fund, Oct 2026 | $250M (SEC Form D, 2026) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Audere | VC firm | Austin, TX | Growth | Biotech, Cybersecurity, AI, Robotics | New fund, Oct 2026 | $100M (SEC Form D, 2024) | 4 Nov 2026 | 8 names, firm email · Unlock |
| JSTAR Capital | VC firm | Austin, TX | Growth | Biotech, Healthtech, AI, Fintech | New fund, Aug 2026 | $100M (SEC Form D, 2025) | 4 Nov 2026 | 8 names · Unlock |
| Highland Europe | VC firm | London, United Kingdom | Growth | Biotech, AI, Cybersecurity, SaaS | New fund, Jul 2026 | €1.1B (own site) | 4 Nov 2026 | 8 names · Unlock |
| Arcventis Health Partners | VC firm | New York, NY | Growth | Biotech, Healthtech, Medtech | New fund, Sep 2026 | $33M (SEC Form D, 2025) | 4 Nov 2026 | 4 names, firm email · Unlock |
| Claret Capital Partners | Venture debt | London, United Kingdom | Series B, Growth, Late stage | Biotech, Healthtech, Climate Tech, SaaS | New deal, Oct 2026 | €575M (own site) | 4 Nov 2026 | 8 names · Unlock |
| THP | VC firm | San Francisco, CA | Growth | Biotech, Healthtech, Industrial Tech, Medtech | Portfolio news, Apr 2026 | $79M (SEC Form D, 2022) | 5 Nov 2026 | 1 name, firm email · Unlock |
| MVM Partners LLP | VC firm | Boston, MA | Growth | Biotech, Healthtech, Medtech | Portfolio news, Jun 2026 | $1.0B (SEC Form ADV) | 5 Nov 2026 | No contact on file |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | $2.8B (own site) | 7 Nov 2026 | 1 name, firm email · Unlock |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Biotech, Medtech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 7 Nov 2026 | No contact on file |
| Eckuity Capital | VC firm | New York, NY | Growth | Biotech, Healthtech, Medtech | New fund, Jun 2026 | $300M (SEC Form D, 2026) | 4 Nov 2026 | 1 name · Unlock |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Biotech, Healthtech, Edtech, Developer Tools | Portfolio news, Oct 2026 | £3.0B (own site) | 4 Nov 2026 | 8 names · Unlock |
| Outlier Ventures | VC firm | United Kingdom | Pre-seed, Seed, Series A, Growth | Biotech, AI, Robotics, Fintech | New deal, Oct 2026 | $500M (own site) | 4 Nov 2026 | LinkedIn page · Unlock |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| 819 Capital Partners | VC firm | Deventer, Netherlands | Seed, Series A, Growth | Biotech, Healthtech, Medtech, Generalist | Portfolio news, Sep 2026 | €100M (own site) | 7 Nov 2026 | 1 name, firm email · Unlock |
| BroadOak Capital Partners | VC firm | Bethesda, MD | Growth | Biotech, Healthtech, Industrial Tech, SaaS | Portfolio news, Apr 2026 | $11M (SEC Form D, 2021) | 5 Nov 2026 | 8 names · Unlock |
| Sofinnova Partners | VC firm | France (London office) | Seed, Series A, Series B, Growth | Biotech, Healthtech, Fintech, Agritech | New fund, Nov 2025 | €4.0B (own site) | 5 Nov 2026 | 8 names · Unlock |
| Signet Healthcare Partners | VC firm | New York, NY | Growth | Biotech, Industrial Tech, Developer Tools, Healthtech | Portfolio news, May 2025 | $300M (SEC Form D, 2022) | 5 Nov 2026 | 8 names · Unlock |
| Agent Capital | VC firm | Waltham, MA | Seed, Growth | Biotech, Healthtech | New fund, Feb 2026 | $100M (SEC Form D, 2021) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Cambridge Capital Group | Angel network | Cambridge, United Kingdom | Seed, Growth | Biotech, Industrial Tech, AI, Developer Tools | New fund, Oct 2026 | £50M (own site) | 4 Nov 2026 | 2 names · Unlock |
| Archangels | Angel network | Edinburgh, United Kingdom | Pre-seed, Seed, Series A, Growth | Biotech, Media, Deep Tech, Healthtech | Portfolio news, Nov 2026 | £10M (own site) | 4 Nov 2026 | 8 names, firm email · Unlock |
| SHS Capital | Fund manager | Tübingen, Germany | Growth | Biotech, Healthtech, Medtech | New fund, Feb 2026 | €270M (own site) | 7 Nov 2026 | 5 names, firm email · Unlock |
| Wellington Partners | VC firm | Munich, Germany | Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, May 2026 | €210M (own site) | 4 Nov 2026 | 8 names · Unlock |
You are seeing 25 of 109. The full list adds 84 more investors and 569 named decision-makers.
One-time payment. No subscription. No account.
Or get the free sample.
How these 109 break down
By region
| Region | On this list | Share |
|---|---|---|
| United States | 44 | 40% |
| United Kingdom | 34 | 31% |
| Europe | 31 | 28% |
By US state
| US state | On this list | Share |
|---|---|---|
| California | 11 | 10% |
| New York | 7 | 6% |
| Massachusetts | 5 | 5% |
| Texas | 3 | 3% |
| Florida | 3 | 3% |
| Connecticut | 3 | 3% |
| Washington | 2 | 2% |
| Maryland | 2 | 2% |
| Iowa | 2 | 2% |
By European country
| European country | On this list | Share |
|---|---|---|
| France | 7 | 6% |
| Germany | 7 | 6% |
| Netherlands | 5 | 5% |
| Sweden | 3 | 3% |
| Spain | 3 | 3% |
| Luxembourg | 3 | 3% |
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 74 | 68% |
| Fund manager | 13 | 12% |
| Government or university fund | 7 | 6% |
| Angel network | 5 | 5% |
| Venture debt | 4 | 4% |
| SEIS/EIS fund | 3 | 3% |
Method and limits
- Source
- 45 of the 109 rows carry an SEC filing (Form D or Form ADV). All 109 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at growth-stage.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 7 Nov 2026.
- Fill rates
- Of 109 rows: stage 109, sector 109, fund size 74, website 109. In the paid file: named decision-makers on 99 rows, firm email on 60, LinkedIn page on 72, check size on 28.
- Corrections
- Email [email protected] or use the update form. We act within 5 working days.
Questions
How many growth-stage biotech investors are there?
We list 109 as of November 2026. 55 of the 109 have a fund filing or a dated deal in the last 12 months.
Which growth-stage biotech investors raised a new fund in the last 12 months?
16 of the 109 have a fund filing dated in the last 12 months. The most recent on this list are Audere (Oct 2026), K5 Global (Oct 2026) and NewVale Capital (Oct 2026).
What is the typical fund size of growth-stage biotech investors?
The median fund size on file for this list is $100M, across the 27 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 82 do not disclose a size there.
How do I contact growth-stage biotech investors?
The paid file holds 569 named decision-makers across 99 of these 109 and a firm email for 60. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.
Where does the data on growth-stage biotech investors come from?
45 of the 109 rows have an SEC filing on file (Form D or Form ADV) and 64 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 7 Nov 2026 at the latest. The whole file is re-verified twice a year.
Broader lists
Narrower lists
Related lists
Growth-stage SaaS investors (344)Growth-stage healthtech investors (316)Seed biotech investors (300)Growth-stage AI investors (295)Growth-stage fintech investors (214)Growth-stage deep tech investors (191)Growth-stage climate tech investors (189)Series A biotech investors (153)Pre-seed biotech investors (148)Growth-stage consumer investors (124)Growth-stage B2B investors (119)Growth-stage medtech investors (107)Growth-stage energy investors (102)Growth-stage cybersecurity investors (92)Growth-stage industrial tech investors (81)Series B biotech investors (73)Growth-stage food and beverage investors (67)Growth-stage mobility investors (55)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to biotech and life sciences and growth-stage. Guide: how many investors to pitch. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.